![Pearls in a shell](/media/hbmpartners/styles/hero_small/public/images/hero-images/hero-portfolio-companies.jpg?h=14832055&itok=DIQpNLis)
Fore Biotherapeutics
Industry
Oncology
Website
HBM contact
Fore Biotherapeutics (former Novellus) is a biotechnology company developing compounds for established oncogene drivers with a high incidence of uncharacterized mutations. Fore Biotherapeutics’ lead program, PLX-8394, is in clinical development for BRAF-mutated tumors without approved therapies.
![Logo Fore Biotherapeutics](/media/hbmpartners/images/portfolio/logo/fore.gif)